Augmentation Strategy in SSRI-Resistant OCD
Two adequate SSRI trials have failed him, and the three real next-step options — antipsychotic augmentation, adding clomipramine, or switching class again — have no guideline-ranked order to choose between.
D.R., a 52-year-old man, supervises the overnight shift at a regional distribution warehouse and remarried eighteen months ago after a divorce five years earlier that he says the OCD "had a lot to do with." He has type 2 diabetes, well controlled on metformin, and mild hypertension managed with lisinopril; neither has changed in over a year.
His OCD centers on contamination fears specific to his warehouse work — he re-washes his hands after touching any inbound shipment, sometimes a dozen times a shift, and has twice been written up for missed quotas because of it. He completed an adequate fluoxetine trial (80 mg for 14 weeks) two years ago with minimal response, then a second adequate trial of fluvoxamine (300 mg for 12 weeks) that ended six months ago, also with minimal response. Both trials were run at guideline-recommended OCD doses for the full recommended duration; his current Y-BOCS is 26, essentially unchanged from where he started fluoxetine.
Two genuinely failed, adequate SSRI trials put him in real treatment-resistant territory, and the next step is where the guidelines stop giving a clear answer. Augmenting his current SSRI with a low-dose atypical antipsychotic has the strongest trial evidence of any augmentation strategy, though the effect size is modest and it adds a real metabolic-monitoring burden on top of his existing diabetes. Adding clomipramine to his SSRI, or switching to it outright, revisits the drug with OCD's single best individual effect size — but combining it with fluvoxamine specifically carries a genuine interaction risk, since fluvoxamine strongly inhibits CYP1A2 and CYP2C19, the enzymes that demethylate clomipramine, raising levels toward cardiotoxicity if the combination isn't dosed and monitored carefully. A third SSRI trial, at a different molecule, remains available and carries the least new risk of the three — and the least evidence of actually working differently this time.
Choosing among three unranked options
Antipsychotic augmentation has more randomized trial support behind it than either of the other two options — low-dose risperidone or aripiprazole added to his current SSRI is where I'd start. The effect size is genuinely modest, and I want that named honestly rather than oversold, but "modest and evidence-backed" beats "larger on paper but less-tested in this exact scenario."
I'd weigh clomipramine more seriously than the augmentation-trial-count alone suggests. He has failed two SSRIs at full guideline doses — that's exactly the patient clomipramine's largest effect sizes were demonstrated in. My hesitation is entirely pharmacokinetic, not about the drug itself: if he stays on fluvoxamine and clomipramine is added on top, fluvoxamine's strong inhibition of CYP1A2 and CYP2C19 will push clomipramine levels up in a way that needs deliberate low-dose start and ECG monitoring, not casual co-prescribing. If we're adding it, I want him off fluvoxamine first, or the interaction managed explicitly, not assumed away.
He also has diabetes that's currently well controlled, and every atypical antipsychotic on the augmentation list carries real metabolic risk — weight gain, dyslipidemia, and in some cases direct glucose effects independent of weight. That doesn't rule augmentation out, but it means it isn't the free-lunch option relative to clomipramine that the trial-count comparison alone implies. I don't think this group actually converges on one right answer today, and I don't think it should pretend to.
Agreed: metabolic labs (fasting glucose, lipid panel) ordered today to establish a fresh baseline regardless of which augmentation path is chosen, and a follow-up visit in two weeks specifically to decide among the three options rather than default into one today.
Explicitly not agreed, and left unresolved rather than forced to a vote: whether antipsychotic augmentation, clomipramine combination, or a third SSRI trial is the right next step. All three voices held their positions at the end of the discussion. The one point of real consensus was procedural, not clinical — if clomipramine is eventually chosen, fluvoxamine must either be tapered off first or the interaction actively managed with dose reduction and ECG follow-up, not layered on without adjustment.